IMNM - Company ID 0001472012
The table below shows Immunome Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $6.94M | $9.04M | $14.02M | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $177.29M | $129.54M | $23.09M | $23.27M | $14.11M | $7.49M |
| SG&A |
Immunome Inc. reported annual revenue of $6.94M for fiscal year 2025. That is down 23.2% from $9.04M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $43.77M |
| $32.95M |
| $19.66M |
| $13.63M |
| $11.09M |
| $4.78M |
| Operating income | -$224.11M | -$305.80M | -$109.53M | -$36.90M | -$25.20M | -$12.26M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$212.39M | -$292.96M | -$106.81M | -$36.90M | -$24.71M | -$17.84M |
| EPS (diluted) | -$2.43 | -$5.00 | -$5.38 | -$3.09 | -$2.14 | -$5.26 |